| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |